Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.

We describe a case of CMV ventriculoencephalitis in a severely immunocompromised bone marrow transplant recipient who was receiving combination therapy with ganciclovir and foscarnet for treatment of viremia and retinitis. Analysis of sequential viral isolates recovered from the patient's cerebrospinal fluid suggested that disease developed because of the presence of viral resistance and, possibly, low tissue penetration of antiviral agents.

[1]  C. Crumpacker,et al.  Sequencing of Cytomegalovirus UL97 Gene for Genotypic Antiviral Resistance Testing , 2001, Antimicrobial Agents and Chemotherapy.

[2]  C. Crumpacker,et al.  Interstrain Variation in the Human Cytomegalovirus DNA Polymerase Sequence and Its Effect on Genotypic Diagnosis of Antiviral Drug Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[3]  A. Erice.  Resistance of Human Cytomegalovirus to Antiviral Drugs , 1999, Clinical Microbiology Reviews.

[4]  J. Cherrington,et al.  Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments , 1998, Journal of Virology.

[5]  D. Jabs,et al.  Cytomegalovirus Retinitis and Viral Resistance: Ganciclovir Resistance , 1998 .

[6]  D. Jabs,et al.  Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. , 1998, The Journal of infectious diseases.

[7]  A. Garrett,et al.  Combination Antiviral Therapy for Cytomegalovirus Disease in Patients with AIDS , 1997, The Annals of pharmacotherapy.

[8]  W. Dowdle.  The 1976 Experience , 1997 .

[9]  W. Freeman,et al.  High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. , 1997, The Journal of infectious diseases.

[10]  H. Balfour,et al.  Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. , 1997, The Journal of infectious diseases.

[11]  D. Clifford,et al.  Cytomegalovirus Encephalitis , 1996, Annals of Internal Medicine.

[12]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[13]  J. McCutchan.  Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  V. Vullo,et al.  Cytomegalovirus encephalitis in two patients with AIDS receiving ganciclovir for cytomegalovirus retinitis. , 1994, The Journal of infection.

[15]  S. Berman,et al.  The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. , 1994, The American journal of medicine.

[16]  V. Mathews,et al.  Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS) , 1994, Neurology.

[17]  U. Hengge,et al.  Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis , 1993, Antimicrobial Agents and Chemotherapy.

[18]  R. Bonomo,et al.  Cytomegalovirus Ventriculoencephalitis in AIDS: A Syndrome with Distinct Clinical and Pathologic Features , 1993, Medicine.

[19]  R. Hamatake,et al.  Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect binding and stimulation by its accessory protein UL42 without affecting basal polymerase activity , 1993, Journal of virology.

[20]  R. Champlin,et al.  Cytomegalovirus infections after allogeneic bone marrow transplantation. , 1990, Reviews of infectious diseases.

[21]  H. Balfour,et al.  Human pharmacokinetics of the antiviral drug DHPG , 1986, Clinical pharmacology and therapeutics.